Expanding patient access to immunotherapies by shrinking processing time to days from weeks and costs to one-tenth of current amount will be the impact of Draper’s end-to-end bioprocessing system. Integrating a complicated multistep process into a closed, modular, benchtop system will enable effective, safe biomanufacturing near patients—helping to save lives.
Improved efficiency at every step increases the yield of cells; as efficiencies compound from step to step they reduce time needed for cell expansion. Acoustophoresis separates cells continuously using ultrasonics, achieving better cell viability than centrifugation; Draper is working on making acoustophoresis label-free. Draper’s device demonstrates standard levels of transduction efficiency—in 90 minutes using at least 50% less therapeutic viral vector. During transfection the system continuously processes each hour one billion cells, which spend only seconds in the electroporation buffer, protecting cell viability. Precision microfluidics control flow precisely.
The end-to-end system standardizes processing of cell and gene therapies, increasing efficiency and quality control while decreasing costs and wait times. Draper sees a near future when its system will need only eight hours to process patient samples—making immunotherapy the standard treatment.
Draper Signs Agreement with Kite to Accelerate Development of Cancer Immunotherapies
The Next Big Advance in CAR T-cell Treatment Will Be Smarter Cell Therapy Production
Draper device equips CAR T-cell therapy developers with a streamlined bioprocessing method designed to lower cost, improve efficiency and broaden patient access
Draper Brings Scalability to CAR T-Cell Bioprocessing
Company’s microfluidic system designed for new cell therapies
Access Our Capabilities
We push boundaries and deliver the capabilities you need.